CT 327 in the treatment of psoriasis vulgaris

• Research type

  Research Study

• Full title

  CT 327 in the treatment of psoriasis vulgaris: A Randomized, Double-Blind, Placebo Controlled Phase II, Multi-Centre, Study of the Efficacy and Safety of CT 327, a topical cream formulation of Pegylated K252a, when administered twice daily for Eight Weeks to Patients with Mild to Moderate Psoriasis Vulgaris

• IRAS ID

  58698

• Contact name

  John Robinson

• Sponsor organisation

  Creabilis Sàrl

• Eudract number

  2010-021207-25

• Clinicaltrials.gov Identifier

  NCT00995969

• Research summary

  The aims of this study are to investigate the efficacy and safety of CT 327, when applied twice daily as a topical cream to lesions of Psoriasis Vulgareas (PV) in comparison to placebo (inactive cream). Patients with mild to moderate PV will receive placebo on a target lesion on one side of their body and matching CT 327 on a comparable target lesion on the opposite side of their body. The treatment period is 8 weeks during which time assessments of safety and efficacy will be done at weeks 2, 4 and 8.

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  10/H0502/52

• Date of REC Opinion

  5 Aug 2010

• REC opinion

  Favourable Opinion